KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Equity (2018 - 2025)

Esperion Therapeutics' Return on Equity history spans 8 years, with the latest figure at 0.06% for Q4 2025.

  • For Q4 2025, Return on Equity rose 3.0% year-over-year to 0.06%; the TTM value through Dec 2025 reached 0.06%, up 3.0%, while the annual FY2025 figure was 0.07%, 6.0% down from the prior year.
  • Return on Equity reached 0.06% in Q4 2025 per ESPR's latest filing, down from 0.26% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 1.13% in Q2 2021 to a low of 0.03% in Q4 2024.
  • Average Return on Equity over 5 years is 0.57%, with a median of 0.6% recorded in 2023.
  • The largest YoY upside for Return on Equity was 607bps in 2021 against a maximum downside of -1675bps in 2021.
  • A 5-year view of Return on Equity shows it stood at 0.98% in 2021, then fell by -22bps to 0.76% in 2022, then plummeted by -35bps to 0.5% in 2023, then crashed by -93bps to 0.03% in 2024, then surged by 87bps to 0.06% in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Return on Equity are 0.06% (Q4 2025), 0.26% (Q3 2025), and 0.27% (Q2 2025).